Home・Список акций・MacroGenics Inc

MacroGenics Inc

Закрыт

СекторЗдравоохранение

4.23 -0.7

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.12

Макс.

4.28

Ключевые показатели
By Trading Economics
Доход	56M 20M
Продажи	12M 33M
Прибыль на акцию	-0.27
Рентабельность продаж	59.439
Сотрудники	293
EBITDA	-34M -65M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+62.04% upside

Дивиденды
By Acuity
Следующий отчет о доходах	10 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-5.2M 254M
Предыдущая цена открытия	4.93
Предыдущая цена закрытия	4.23

Новостные настроения

By Acuity

50%

138 / 340 Рейтинг в Healthcare

MacroGenics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 авг. 2026 г., 20:02 UTC

MacroGenics Inc shares are lower today amid broader market volatility linked to potential interest rate hikes. No specific company news was identified.

20 авг. 2026 г., 20:06 UTC

MacroGenics shares are lower today, pulling back from earlier session highs amid rising crude oil prices and increased U.S. Treasury yields.

19 авг. 2026 г., 21:01 UTC

MacroGenics Inc shares are lower in after-market trading, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

18 авг. 2026 г., 19:46 UTC

MacroGenics Inc. shares are gaining during Tuesday's session, despite earlier pulling back from a session high amid rising Treasury yields and inflation concerns.

17 авг. 2026 г., 19:51 UTC

MacroGenics Inc shares are lower today amid unusual volatility, having hit a session low before a brief recovery. No specific news was identified.

14 авг. 2026 г., 19:21 UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

13 авг. 2026 г., 21:01 UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

12 авг. 2026 г., 19:46 UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

11 авг. 2026 г., 22:26 UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

4 авг. 2026 г., 19:46 UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

31 июл. 2026 г., 20:06 UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

29 июл. 2026 г., 20:09 UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

28 июл. 2026 г., 17:03 UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

27 июл. 2026 г., 20:01 UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

24 июл. 2026 г., 20:01 UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

22 июл. 2026 г., 19:51 UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

21 июл. 2026 г., 19:06 UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Сравнение c конкурентами

Изменение цены

MacroGenics Inc Прогноз

Целевая цена

By TipRanks

62.04% рост

Прогноз на 12 месяцев

Средняя 7 USD 62.04%

Максимум 11 USD

Минимум 4 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для MacroGenics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

4 ratings

Покупка

Удержание

Продажа

Основано на мнении 4 аналитиков, присваивавших рейтинги акциям MacroGenics Inc – Данные за последние 3 месяца.

Настроения

By Acuity

138 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.